Literature DB >> 27908621

Radiotherapy With Curative Intent in Patients With Early-stage, Medically Inoperable, Non-Small-cell Lung Cancer: A Systematic Review.

Conrad B Falkson1, Emily T Vella2, Edward Yu3, Medhat El-Mallah4, Robert Mackenzie2, Peter M Ellis5, Yee C Ung6.   

Abstract

Patients with early-stage non-small-cell lung cancer (NSCLC) who are unable to undergo surgery can be offered radiation therapy (RT). Previously, conventional RT was offered; however, newer techniques such as stereotactic body RT (SBRT) have become available. The objective of the present systematic review was to investigate the effectiveness of RT with curative intent in patients with early-stage medically inoperable NSCLC. MEDLINE, EMBASE, and the Cochrane Library were searched for studies comparing stereotactic RT with curative intent compared with observation or other types of RT for early-stage, medically inoperable, NSCLC. Comparisons of radiation dosing or fractionation schedules for SBRT were included. We include 4 systematic reviews and 52 observational studies. The evidence suggests that SBRT compared with observation or other forms of RT, such as accelerated hypofractionated RT, 3-dimensional conformal RT, conventional fractionated RT, external beam RT, proton beam therapy, and carbon ion therapy, could have similar or improved results in survival or local control, with similar or fewer adverse effects. Evidence also suggests that local tumor control and survival were associated with the biologically effective dose (BED) for SBRT. Several studies suggested a cutoff of approximately 100 BED correlated significantly with patient outcomes. The presented evidence suggests that SBRT compared with other forms of RT is a reasonable treatment option for patients with medically inoperable early-stage NSCLC.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dose fractionation; Hypofractionation; NSCLC; Stereotactic ablative radiation therapy; Stereotactic body radiation therapy

Mesh:

Year:  2016        PMID: 27908621     DOI: 10.1016/j.cllc.2016.10.008

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  12 in total

1.  Guideline for radiotherapy with curative intent in patients with early-stage medically inoperable non-small-cell lung cancer.

Authors:  C B Falkson; E T Vella; E Yu; M El-Mallah; R Mackenzie; P M Ellis; Y C Ung
Journal:  Curr Oncol       Date:  2017-02-27       Impact factor: 3.677

2.  Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy.

Authors:  Michelle Iocolano; Aaron T Wild; Margaret Hannum; Zhigang Zhang; Charles B Simone; Daphna Gelblum; Abraham J Wu; Andreas Rimner; Annemarie F Shepherd
Journal:  Acta Oncol       Date:  2019-10-12       Impact factor: 4.089

Review 3.  Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer.

Authors:  Susanne Temming; Martin Kocher; Erich Stoelben; Lars Hagmeyer; De-Hua Chang; Konrad Frank; Khosro Hekmat; Juergen Wolf; Wolfgang W Baus; Robert Semrau; Christian Baues; S Marnitz
Journal:  Strahlenther Onkol       Date:  2017-08-15       Impact factor: 3.621

4.  A SUVmax-based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage I non-small cell lung cancer: unveiling the role of 18F-FDG PET/CT in clinical decision-making.

Authors:  L Ye; F Xu; S Shi; Z Zeng; X Jin; Y Huang; C Lu; J Gu; D Ge; J He
Journal:  Clin Transl Oncol       Date:  2018-01-11       Impact factor: 3.405

5.  Flattening filter-free technique in volumetric modulated arc therapy for lung stereotactic body radiotherapy: A clinical comparison with the flattening filter technique.

Authors:  Shuri Aoki; Hideomi Yamashita; Akihiro Haga; Kanabu Nawa; Toshikazu Imae; Wataru Takahashi; Osamu Abe; Keiichi Nakagawa
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

6.  A comparison of two modalities of stereotactic body radiation therapy for peripheral early-stage non-small cell lung cancer: results of a prospective French study.

Authors:  Line Claude; Magali Morelle; Marc-André Mahé; David Pasquier; Pierre Boisselier; Pierre Yves Bondiau; Emmanuel Touboul; Karine Peignaux-Casasnovas; Isabelle Martel-Lafay; Frederic Gassa; Lionel Perrier; Sophie Dussart; Veronique Beckendorf
Journal:  Br J Radiol       Date:  2020-09-24       Impact factor: 3.039

7.  Tumor necrosis factor-related apoptosis-inducing ligand additive with Iodine-131 of inhibits non-small cell lung cancer cells through promoting apoptosis.

Authors:  Ning Yang; Shuzhan Yao; Dong Liu
Journal:  Oncol Lett       Date:  2018-05-04       Impact factor: 2.967

8.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.

Authors:  Rui-Xue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-05-01

9.  Appropriate surgical modalities for stages T2a and T2b in the eighth TNM classification of lung cancer.

Authors:  Fenglong Bie; Xiao Qu; Xudong Yang; Zhaofei Pang; Yufan Yang; Shaorui Liu; Wei Dong; Jiajun Du
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

10.  The p53-53BP1-Related Survival of A549 and H1299 Human Lung Cancer Cells after Multifractionated Radiotherapy Demonstrated Different Response to Additional Acute X-ray Exposure.

Authors:  Margarita Pustovalova; Lina Alhaddad; Nadezhda Smetanina; Anna Chigasova; Taisia Blokhina; Roman Chuprov-Netochin; Andreyan N Osipov; Sergey Leonov
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.